Title Physician

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

NCT ID : N/A
Protocol Number : CBI_2019_SLNBprosp_001
Phase : N/A
Location : Santa Monica, CA
Richard Essner, M.D.

A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment

NCT ID : 03978611
Protocol Number : CA224-083
Phase : 1/2
Location : Santa Monica, CA
Timothy Kristedja, M.D.

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

NCT ID : 04526899
Protocol Number : BNT111-01
Phase : 2
Location : Santa Monica, CA
Przemyslaw Twardowski, M.D.

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

NCT ID : 04410445
Protocol Number : 20-214-29/CA045-022
Phase : 3
Location : Santa Monica, CA
Steven O' Day, M.D.

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C)

NCT ID : 04303169
Protocol Number : MK-3475-02C
Phase : 3
Location : Santa Monica, CA
Timothy Kristedja, M.D.

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B)

NCT ID : 04305054
Protocol Number : MK-3475-02B
Phase : 3
Location : Santa Monica, CA
Przemyslaw Twardowski, M.D.

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

NCT ID : 04382664
Protocol Number : UV1-202
Phase : 2
Location : Santa Monica, CA
Przemyslaw Twardowski, M.D.

A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy

NCT ID : 03978611
Protocol Number : CA224-083
Phase : 1/2a
Location : Santa Monica, CA
Steven O' Day, M.D.

A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2
Location : Santa Monica, CA
Steven O' Day, M.D.

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT ID : 03425643
Protocol Number : MK-3475-671
Phase : 3
Location : Santa Monica, CA
Steven O' Day, M.D.